Individual head and neck screening: Initiating a dialogue about best approach

Am J Otolaryngol. 2022 Mar-Apr;43(2):103302. doi: 10.1016/j.amjoto.2021.103302. Epub 2021 Dec 3.

Abstract

Purpose: We aim to investigate the true benefits of free individual HNC screening in a high-risk urban population as well as the associated risks.

Materials and methods: This is a retrospective descriptive study. Free HNC screening was performed from 2014 to 2019. Participants were issued a questionnaire at the time of screening. After exemption by the Institutional Review Board, completed screening questionnaires were entered into a database and descriptive statistics were generated. The primary outcome measure for this study was the detection rate for HNC. We hypothesized that screening would be low yield based on previous studies (Gogarty et al., 2016).

Results: This was a volunteer sample with a total of 410 participants, and the highest yield screening year was 2019 (n = 187). For all years, the cancer detection rate was 0%. In 2019, 134 (77.9%) of participants did not recognize the early symptoms of HNC, and 120 (73.2%) reported the screening program increased their awareness of the disease. 13 (7.6%) reported HPV vaccination while 126 (71.2%) were unaware that HPV has been linked with head and neck cancer.

Conclusions: HNC screening is an excellent opportunity for education regarding HNC risk factors. However, it is not a cost-effective use of physician time, does not increase detection rates even in high-risk segments of the general population, and is not completely without risk in the context of COVID-19. Perhaps the focus of HNC screening should shift from individualized screening to education and health promotion.

Keywords: Cancer screening; HPV awareness; Head and neck cancer; Screening techniques.

MeSH terms

  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Head and Neck Neoplasms* / diagnosis
  • Head and Neck Neoplasms* / epidemiology
  • Humans
  • Mass Screening
  • Retrospective Studies
  • SARS-CoV-2